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Aim: In this work we illustrate limits and challenges associated with the use of pharmacological inhibitors
to study how nanomedicines enter cells and show how such limits can be overcome.Materials & methods:
We selected a panel of six common pharmacological inhibitors and a model nanoparticle–cell system. We
tested eventual toxicity by measuring cell viability. We confirmed drug efficacy by measuring the uptake
of control markers for the pathways involved by flow cytometry and fluorescence microscopy. Results
& conclusion: We show how to optimize the use of pharmacological inhibitors and interpret the results
generated. Furthermore, we demonstrate that some inhibitors cannot be used for nanomedicine studies
because they lose their efficacy when serum is added, as required for nanoparticle exposure to cells.
First draft submitted: 17 November 2018; Accepted for publication: 15 March 2019; Published online:
18 June 2019
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Nano-sized drug carriers are used to improve the targeted delivery of drugs to their site of action [1–3]. Several
products are now on the market and extensive research is still ongoing on how to further improve carrier design
and nanomedicine efficacy. Recent debates within the field have highlighted that a better understanding of the
mechanisms by which these materials are processed at cellular level is one of the factors that could enable such
improvements [4–6].
Within this context, a very first and central question is how nanomedicines are internalized by cells.
Cells use different processes to internalize extracellular materials. Several mechanisms of endocytosis have been
identified and extensive reviews are available to summarize the key aspects of each of these different pathways. The
field is very active and constantly updating [7–10].
It is generally recognized that nanomedicines typically enter cells by active processes, thus some form of endo-
cytosis. These objects are, in fact, too large to simply diffuse inside cells [11,12] unless specifically engineered to do
so [13]. However, in many cases the details of the molecular machinery involved are still unclear, as well as very
challenging to characterize.
Several studies have tried to determine how the mechanisms of uptake change with nanoparticle (NP) type as
a function of their size, charge, shape and other NP parameters [11,12,14,15]. For instance, charge density and the
type of charge (positive, negative) can affect the mechanisms NPs use to enter cells, and surface hydrophobicity
is also an important parameter affecting uptake [16–22]. More recently, it has emerged that also the medium in
which the nanomedicines are dispersed and the resulting biomolecule corona on their surface can affect the entry
mechanisms [23,24].
Overall, several methods are available to study transport in cells. Most classic approaches are based on methods
to block a certain portal of entry and – in this way – determine its involvement in the uptake of the material
of interest. These include, for instance, the use of pharmacological inhibitors and RNA interference or other
approaches to knock down or transiently block the expression of key proteins involved in endocytosis. However,
when attempting to block transport, cells can adapt by overactivating alternative mechanisms normally less relevant,
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Table 1. Overview of the selected transport inhibitors.
Inhibitor name Mechanism of action Pathways involved Marker
EIPA Na+/H+ exchanger pump inhibitor;
blocks Rac1 and Cdc42 signaling [30,31]
Macropinocytosis TRITC–Dextran [29]
CP AP2 inhibitor; blocks endosome
recycling [32]
CME Dil–LDL [33,34]
MBCD Cholesterol depletion Multiple pathways (lipid-rafts and
caveolae-mediated endocytosis) [26]
BODIPY FL C5-Lactosylceramide/BSA
complex (LacCer) [28, 35]
Dyn Dynamin inhibitor [36,37] Multiple pathways [38] Dil-LDL [33,34]
NZ Binds to tubulin, blocking microtubule
polymerization [39]
CME [40], macropinocytosis and other
mechanisms [41,42]
Tubulin staining (-Tubulin)
CytD Mycotoxin that binds actin and blocks
its polymerization [43]
Macropinocytosis [44], CME [45],
CIE [38]
Actin staining (phalloidin)
The table shows the transport inhibitors selected for this study, their mechanism of action and pathways involved. The control markers used to test their efficacy are also indicated.
CIE: Clathrin independent endocytosis; CME: Clathrin-mediated endocytosis; CP: Chlorpromazine hydrochloride; CytD: Cytochalasin; Dil: 3,3’-dioctadecylindocarbocyanine; Dyn: Dyna-
sore; EIPA: 5-(N-Ethyl-N-isopropyl)amiloride; MBCD: Methyl--cyclodextrin; NZ: Nocodazole; TRITC: Tetramethylrhodamine.
or by overcompensating for the blocked function or protein [25]. This makes the interpretation of the role of certain
pathways in the unperturbed cells complicated [26]. Next to these methods, imaging-based approaches can be used
to directly visualize uptake and determine whether the material of interest is associated with key endocytic structures
or proteins [27].
Among all of these methods, most studies on the uptake of nanomedicines make use of pharmacological
inhibitors [11,14]. They are often preferred because they have a very fast action, thus limiting the possibility for cells
to adapt, and they are seemingly easy to use.
However, it is well known that pharmacological inhibitors possess limits associated with both their poor specificity
and toxicity, and that their efficacy can strongly vary with the cell line in which they are used [28,29].
Within this context, here we have selected a panel of six representative pharmacological inhibitors among those
most commonly applied in nanomedicine uptake studies [11,14,26–29]. The selected compounds are active on different
elements of the uptake machinery and all major uptake mechanisms (as summarized in Table 1).
More in detail, the following compounds were chosen:
• Chlorpromazine and EIPA(5-(N-ethyl-N-isopropylamiloride), typically used as inhibitors of (respectively)
clathrin-mediated endocytosis and macropinocytosis;
• Methyl-β-cyclodextrin (MBCD) to determine the effect of cholesterol depletion;
• Nocodazole to determine the role of microtubules;
• Cytochalasin D to determine the role of actin;
• The dynamin inhibitor dynasore.
Chlorpromazine is a compound used to block clathrin-mediated endocytosis [28,32]. Chlorpromazine is a cationic
amphiphilic drug which inhibits the function of AP2, one of the key adaptor proteins in clathrin-mediated
endocytosis. Chlorpromazine is also known to trap receptors inside the endosomes, thus blocking their recycling [32].
Therefore, this compound interferes with clathrin-mediated endocytosis at multiple levels.
Similarly, amiloride and its derivative EIPA are used as inhibitors of macropinocytosis: they block the Na+/H+
exchanger pump in the plasma membrane, thus inhibiting macropinocytosis as a consequence of their interference
with the pH of the cytosol close to the cell membrane where macropinosomes form [30,31]. The resulting acidification
also blocks Rac1 and Cdc42 signaling, essential for macropinocytosis.
The other selected pharmacological inhibitors have a more direct mechanism of action in blocking a key
component of endocytosis. More in detail, cytochalasin D is a mycotoxin that blocks actin polymerization by
binding to the barbed end of F-actin [43]. Actin is known to be involved in several pathways. This means that
caution should be taken into interpreting cytochalasin D as an inhibitor of, for instance, macropinocytosis [44],
since also clathrin-mediated endocytosis [45] and several clathrin-independent endocytosis mechanisms [38] depend
on actin.
Similarly, nocodazole is a compound that binds to tubulin, blocking microtubule polymerization [39]. Mi-
crotubules are essential components for clathrin-mediated endocytosis [40], macropinocytosis and possibly other
mechanisms [41,42] and they also control vesicle intracellular trafficking [46].
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Dynasore is commonly used to block dynamin, a key protein for vesicle fission [36,37], although its specificity is
sometimes questioned [47]. Multiple pathways depend on dynamin activity and the involvement of dynamin is a
common way to classify endocytosis [38].
Finally, MBCD is a common agent for cholesterol depletion. Cholesterol depletion can be a very disruptive
treatment for cells, since cholesterol is essential for maintaining proper membrane permeability and fluidity.
Moreover, exposing cells to MBCD affects not only caveolae-mediated endocytosis, as often implied, but almost
every endocytic mechanism, strongly depending on the concentration used and cells tested [26].
Overall, none of these latter four compounds (cytochalasin D, nocodazole, dynasore, MBCD), alone, allow the
identification of a specific pathway, since they all affect components of the transport machinery which are involved
in multiple mechanisms.
The selected panel allows us to illustrate the challenges associated with the use of pharmacological inhibitors
while trying to characterize the uptake of one model NP–cell system.
We use this example to discuss limits related to the mechanism of action of the selected compounds; we also show
how the interpretation of the results generated can be complicated by inhibitor toxicity, and how this – if overlooked
– can lead to wrong conclusions. Next, we illustrate the need for control markers to verify and demonstrate efficient
inhibition in the cells and conditions tested, and discuss challenges associated with the selection and availability
of such controls. Finally, we also show specific limits when these compounds are used for nanomedicine uptake
studies. Overall, the approaches and experiments presented can be used to set up and optimize the use of these and
other pharmacological inhibitors for nanomedicine uptake studies, and to avoid misinterpretation of the results
that can be obtained without similar optimization.
Materials & methods
Cell culture
HeLa cells (ATCC CCL-2™) were grown in a complete cell culture medium (cMEM) composed by MEM (Gibco™)
supplemented with 10% v/v fetal bovine serum (FBS, Gibco™) under standard conditions (37◦C, 5% CO2). Cells
at passages between four and maximum 20 were used.
NP characterization
Plain fluorescently labeled silica NPs (SiO2 NPs) of 50 nm diameter, with excitation and emission wavelengths
of, respectively, 569 and 585 nm were purchased from Kisker Biotech. NP hydrodynamic diameter by dynamic
light scattering and ζ-potential were measured using a Malvern Zetasizer Nano ZS (Malvern Instruments, Malvern,
UK) using disposable capillary cells. In order to assess NP stability, 100 μg/ml NPs were dispersed in 1 ml of
dH2O, PBS or MEM supplemented with 10% v/v fetal bovine serum (FBS, Gibco™; cMEM) and measured at
20◦C immediately or after 1 and 24 h at 37◦C, 5% CO2. Results are the average of five runs of at least three
measurements.
Studies with pharmacological inhibitors of endocytosis
In order to characterize NP uptake mechanisms, HeLa cells were treated with inhibitors of endocytosis prior to
and during exposure to the NPs. Briefly, 50,000 cells/well were seeded in a 24-well plate (Greiner Bio-One)
24 h prior to the experiments. Then, cells were preincubated for 10 or 20 min (in the case of nocodazole) in
cMEM with the different inhibitors at different concentrations in order to determine best conditions for their
use. The optimized conditions were as follows: 5-(N-ethyl-N-isopropyl)amiloride (EIPA) 100 μM, chlorpro-
mazine hydrochloride 10 μg/ml, MBCD 2.5 mg/ml (all from Sigma-Aldrich, MO, USA), dynasore 25 μg/ml
and nocodazole 5 μM (Biovision, CA, USA), cytochalasin D 2.5 μg/ml (ThermoFisher Scientific, MA, USA).
After preincubation, 100 μg/ml SiO2 NPs in cMEM were added to cells with or without the different drugs.
Drug efficacy was assessed by measuring uptake of fluorescently labeled control markers. Total 2 μg/ml of 3,3’-
dioctadecylindocarbocyanine-labeled (Dil)-LDL, ThermoFisher Scientific) in MEM with or without 10% FBS or
15 μg/ml of fluorescently labeled human transferrin (Alexa546-TF, ThermoFisher Scientific) were used as markers
for clathrin-mediated endocytosis. Total 1 μg/ml of BODIPY FL C5-Lactosylceramide/BSA complex (LacCer,
Thermo Fisher Scientific) in MEM with or without 10% FBS was used as a marker for caveolae-mediated and lipid
raft dependent endocytosis. Total 250 μg/ml TRITC 10 kDa Dextran (ThermoFisher Scientific) in cMEM was
used as a marker for macropinocytosis. Samples were collected and prepared for flow cytometry as described below.
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Alternatively, the efficacy of cytochalasin D and nocodazole on, respectively, actin or microtubule disruption was
assessed by immunohistochemistry as described in the Supplementary Information.
Flow cytometry analysis
Cell fluorescence intensity following uptake of NPs and control markers was measured by flow cytometry. After
different exposure times, cells were washed once with cMEM and twice with phosphate-buffered saline (PBS) in
order to remove the excess of fluorescent NPs and markers and limit the presence of eventual NPs adhering outside
of the cell, which could affect the flow cytometry measurement [48,49]. Subsequently, cells were collected using
0.05% trypsin–EDTA, centrifuged and resuspended in PBS for measurement. Cell fluorescence was recorded using
a Cytoflex Flow Cytometer (Beckman Coulter, CA, USA) with a 488 nm laser. Data were analyzed using Flowjo
software (Flowjo, LLC). Double scatter forward and side-scattering plots were used to set gates in order to exclude
cell debris and cell doublets. A total of at least 20,000 cells were acquired per sample and each sample was performed
in triplicate. When, due to toxicity, fewer cells were measured, a symbol has been added on the data point and the
number of cells acquired has been specified in the caption. The results in Figures 1–6 and Supplementary Figures 1,
3 and 4 are expressed as the median cell fluorescence intensity of the obtained distributions, averaged over the three
technical replicates. Error bars are the corresponding standard deviation. In Supplementary Figure 5 and 7, instead,
the uptake results – calculated as described above – in cells exposed to NPs in the presence of a drug inhibitor have
been normalized by the uptake in control cells without drugs. This allows one to obtain a percentage of uptake in
respect to control cells. Supplementary Figure 7 shows the normalized results obtained in at least three independent
experiment replicates, while Figure 7 shows the corresponding averaged results and standard deviations.
MTT assay & immunohistochemistry
Cell viability after treatment with the different inhibitors was assessed via MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) assay. Efficacy of nocodazole and cytochalasin D was assessed by immunostaining.
The detailed methods are included in the Supplementary Information.
Results
As a first step, a panel of pharmacological inhibitors was selected for this study, together with appropriate control
markers to optimize their use. Table 1 summarizes the mechanism of action of the different inhibitors and the
pathways involved.
In order to optimize the use of this kind of compound and avoid misinterpretations, two requirements are
essential: first, testing their efficacy in blocking the pathway of interest and second, testing their toxicity on the
cells chosen for the study. To this aim, here, HeLa epithelial ovarian cancer cells were selected as a model cell line
commonly used both in the endocytosis and in the nanomedicine fields [11,14,50,51].
Thus, in order to test drug efficacy, control molecules entering cells via the mechanism affected by the transport
inhibitors are required. Transferrin and LDL were selected to optimize the use of chlorpromazine in blocking
clathrin-mediated endocytosis [33,34]. In order to test the efficacy of cholesterol depletion by MBCD, the uptake
of LacCer, a glycosphingolipid that resides preferably in lipid rafts and whose uptake depends on cholesterol, was
measured [28,35]. Similarly, fluorescently labeled dextran, a fluid phase marker, was used to test the efficacy of the
amiloride derivative EIPA in blocking macropinocytosis [29]. Finally, for cytochalasin D and nocodazole imaging of
actin and microtubules, respectively, allowed us to easily assess the efficacy of the protocol applied in altering these
structures.
Different doses of the selected inhibitors were applied to HeLa cells and their effect on the uptake of control
markers was tested, together with the effect on the uptake of 50 nm silica, here chosen as a model NP. MTT assay
and light microscopy imaging were used to detect eventual toxicity.
Even when performing simple experiments with control markers, further complications may arise: when we
tested the uptake of transferrin in HeLa cells in the presence of chlorpromazine (Supplementary Figure 1), for
short incubation times, exposure to chlorpromazine led to a strong reduction of transferrin uptake, suggesting
inhibition of clathrin-mediated endocytosis. However, after 1 h, this reduction was fully lost. This could be due
to cells adapting quickly to chlorpromazine and compensating in some way. However, a 1 h pre-exposure to
chlorpromazine led to a strong reduction of transferrin uptake, ruling out this interpretation. Still, also in this case,
after 1 h exposure to transferrin in the presence of chlorpromazine, inhibition was lost. Interestingly, no such loss of
inhibition was observed using LDL as control marker instead of transferrin (Supplementary Figure 1). A possible
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Figure 1. Chlorpromazine to block clathrin-mediated endocytosis. Uptake by flow cytometry of (A&C) 2 μg/ml Dil-LDL in sfMEM and
(B&D) 100 μg/ml red silica nanoparticles in cMEM in HeLa cells exposed to different concentrations of chlorpromazine; the results are the
average and standard deviation over three replicates of median fluorescence intensities of 20,000 cells, except where indicated (X:
average of 2500 cells; Y: average of 13,000 cells); (C&D): the data of (A&B) are normalized for uptake in control cells without
chlorpromazine; (E) viability measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromidefor test and (F) light microscopy
images of HeLa cells exposed for 4 h to chlorpromazine in sfMEM or cMEM (scale bar: 200 μm). % ctrl and ctrl+performed as described in
the methods.
au: Arbitrary units; % ctrl: Normalization; cMEM: Complete cell culture medium; Ctrl+: Positive control; DiL-LDL:
3,3’-dioctadecylindocarbocyanine-labeled low density lipoprotein; sfMEM: Serum free cell culture medium.
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Figure 4. Methyl-β-cyclodextrin to deplete cholesterol. Uptake by flowcytometry of (A) 1 μg/ml LacCer in sfMEM and (B) 100 μg/ml red
silica nanoparticles in cMEM in control cells and cells exposed to 2.5 mg/ml MBCD; (C & D) uptake by flow cytometry of (C) 1 μg/ml LacCer
in sfMEM and cMEM and (D) 100 μg/ml red silica nanoparticles in cMEM in cells exposed to different concentrations of MBCD, normalized
by the uptake in control cells without MBCD. (E) viability measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromidefor
test and (F) light microscopy images of cells exposed for 4 h to different doses of MBCD in cMEM (scale bar: 100 μm). % ctrl and
ctrl+ performed as described in the methods. Flow cytometry data are the average and standard deviation over three replicates of the
median fluorescence intensity of 20,000 cells except where indicated (X = not enough cells [less than 500], Y: average of 5000 cells).
% ctrl: Normalization control; au: Arbitrary units; cMEM: Complete cell culture medium; Ctrl: Control cells; Ctrl+: Positive control; MBCD:
Methyl-β-cyclodextrin; sfMEM: Serum-free cell culture medium.
1540 Nanomedicine (Lond.) (2019) 14(12) future science group















































Figure 5. Cytochalasin D for actin depolymerization. (A) Fluorescence and light microscopy images of HeLa cells
exposed for different times to 2.5 μg/ml cytoD; green: actin staining by TRITC–Phalloidin; blue: DAPI stained
nuclei. Scale bar: 50 and 150 μm, respectively. (B) Uptake by flow cytometry of 100 μg/ml red silica nanoparticles in
complete cell culture medium in control cells and cells exposed to 2.5 μg/ml CytoD (average and standard deviation
over three replicates of the median fluorescence intensity of 20,000 cells); (C) viability by MTT test of cells exposed for
4 h to different doses of CytoD in complete cell culture medium. Normalization and ctrl + performed as described in
the methods.
au: Arbitrary units; Ctrl: Control cells; Ctrl+: Positive control; CytoD: Cytochalasin D; TRITC: Tetramethylrhodamine.
interpretation is that, after longer exposure, transferrin (and not LDL) adheres out of the cell membrane, polluting
the flow cytometry measurements. Alternatively, cells exposed to transferrin in the presence of chlorpromazine may
adapt and use alternative routes for its uptake. Further studies are required to understand this phenomenon.
Supplementary Figure 1 also shows controls for cells exposed to dynasore. As previously mentioned, dynamin
is involved in several pathways including clathrin-mediated endocytosis; thus, we expected dynasore to reduce the
uptake of both LDL and transferrin. Instead, we found that transferrin uptake was only partially reduced, while
LDL uptake was strongly inhibited over time. This is again an example to illustrate the complexity of outcomes,
even when simply setting up similar control experiments.
As mentioned above, 50 nm silica NPs were chosen as a common model used in many cell–NP studies because
of their size, comparable with many drug carriers, and because of their well-known stability, even in cell culture
medium [52,53]. Prior to their application, their size distribution and ζ-potential in different media over time were
determined (Supplementary Figure 2 & Table 1). The results confirmed good dispersion and stability over time,
also in the conditions applied for exposure to cells.
Figure 1 shows the results obtained for cells exposed to chlorpromazine at different concentrations. For the
lower chlorpromazine concentration tested, the inhibition of the control marker LDL was already extremely strong,
suggesting that these conditions are efficient in blocking the pathway (Figure 1A). However, only a minor effect
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Figure 6. Nocodazole to disrupt microtubules. (A) Fluorescence and light microscopy images of HeLa cells exposed for different times to
5 μM nocodazole; red: α-Tubulin staining; blue: 4′,6-diamidino-2-phenylindole-stained nuclei. Scale bar: 50 and 150 μm, respectively. (B)
Uptake by flow cytometry of 100 μg/ml red silica nanoparticles in cMEM in control cells and cells exposed to 5 μM nocodazole (average
and standard deviation over three replicates of the median fluorescence intensity of 20,000 cells); (C) viability by
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromidefor test of cells exposed for 4 h to different doses of nocodazole in complete
cell culture medium. Normalization and ctrl + performed as described in the methods.
au: Arbitrary units; Ctrl: Control cells; Ctrl+: Positive control.
could be observed on NP uptake. NP uptake inhibition was much stronger at higher chlorpromazine concentrations.
However, in these conditions, strong toxicity could be detected (Figure 1B). Thus, the observed reduction in NP
uptake is most likely a simple consequence of the very strong toxicity at higher chlorpromazine concentrations
rather than a proof of uptake by clathrin-mediated endocytosis.
It is important also to note that while NPs were added to cells in the presence of proteins to allow corona formation,
controls with labeled transferrin or LDL are usually performed in absence of serum to avoid competition with
the unlabeled transferrin and LDL already present in the serum. However, it is well known that drug efficacy
can be limited by protein adsorption. Thus, as an ulterior control, uptake of labeled LDL in the presence of
chlorpromazine was also measured in medium containing serum. The results clearly showed that chlorpromazine
efficacy was not affected by the presence of proteins (Supplementary Figure 3). This suggests that the absence of
effect of chlorpromazine on NP uptake was not due to loss of drug efficacy in the presence of serum.
Figure 2 shows a similar study performed on cells exposed to the macropinocytosis inhibitor EIPA. At the lower
concentrations tested only a partial dose-dependent reduction of the uptake of the fluid-phase marker dextran was
obtained (Supplementary Figure 4). At 100 μM EIPA, instead, uptake of dextran was strongly reduced, and at
higher concentrations the effect did not improve further (Figure 2A). In the case of the NPs, 100 μM EIPA gave
only a minor uptake reduction, but the effect was stronger for higher EIPA concentrations (Figure 2B). Cell viability
measurements and microscopy clarified that in these conditions, as observed for chlorpromazine, the reduction
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Figure 7. Overview of uptake inhibition results. Uptake by flow cytometry in HeLa cells exposed to 100 μg/ml red
silica nanoparticles in complete cell culture medium in the presence of 10 μg/ml chlorpromazine, 100 μM EIPA, 5 μM
nocodazole or 2.5 μg/ml cytochalasin D for the indicated times. Data are the averaged mean and standard deviation
of at least three independent experiments, each normalized by the results in control cells without inhibitors (see
Supplementary Figure 7 for details).
% ctrl: Normalization control; EIPA: 5-(N-Ethyl-N-isopropyl)amiloride.
in NP uptake was most likely only a side effect of the strong toxicity on cells (Figure 2C). Another interesting
observation was that when using nontoxic EIPA concentrations (50–100 μM), the effect seemed stronger at the
longer exposure times, suggesting a later involvement of macropinocytosis [54]. Size measurements showed a good
stability of the dispersions up to 24 h (Supplementary Figure 2), excluding that such a result may be connected
to particle agglomeration over time and activation of mechanisms commonly associated with the uptake of larger
objects. Further studies are required to fully clarify these observations.
Figure 3 shows results in cells exposed to dynasore to inhibit dynamin. With this compound, we could observe
a very good inhibition of LDL uptake at concentrations not associated with a decrease in cell viability (Figure 3A
& C). In these conditions, NP uptake was not affected (Figure 3B). However, additional controls with LDL showed
that dynasore efficacy was partially lost when serum was added (Figure 3D). Increasing dynasore concentration only
partially reduced LDL uptake in serum, but still with almost no effect on NP uptake (Figure 3E). Furthermore, at
these higher concentrations, strong toxicity was observed (Figure 3C & F).
Figure 4 shows similar results for MBCD. Cholesterol depletion was extremely effective in blocking uptake of
the control marker LacCer (Figure 4A), while only a minor effect was observed on the uptake of the silica NPs
(Figure 4B). However, as for dynasore, in the presence of serum the efficacy of MBCD was lost (Figure 4D), and
increasing drug concentration only led to strong cell death (Figure 4C & F) without any sign of improved efficacy
on LDL and NP uptake (Figure 4D & E).
Thus, other compounds not sensitive to the presence of proteins should be selected when studying the role of
dynamin and cholesterol in the mechanisms of nanocarrier uptake into cells.
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Figure 5 shows the results obtained with cytochalasin D, with additional optimization in Supplementary Figure
5: immunostaining and light microscopy confirmed drug efficacy (Figure 5A & Supplementary Figure 5A) and no
effect on cell viability (Figure 5C & Supplementary Figure 5B). Interestingly, actin disruption clearly reduced NP
uptake, suggesting a role for actin in the internalization mechanism (Figure 5B).
Finally, Figure 6 shows the results obtained with nocodazole to depolymerize microtubules (see also Supplemen-
tary Figure 6 for further controls). Microtubule disruption led to a reduction of NP uptake (Figure 6B), suggesting
that the cytoskeleton is involved in the mechanism of internalization, or that altering the intracellular trafficking
machinery has an effect on the uptake levels.
Discussion
Several parameters can affect the efficacy and toxicity of pharmacological inhibitors: these include not only the
dose and exposure time, but also the length of the preincubation with the inhibitor, the medium in which they
are dispersed (with or without serum), cell density and cell passage number. For instance, higher cell numbers
may require higher drug concentrations and are typically associated with lower toxicities. Similarly, cells at higher
passage numbers can become less sensitive to these compounds (For this reason, as specified in the materials and
methods, we have used cells up to a maximum of 20 passages to exclude similar effects).
In order to be able to test and optimize all of these parameters, appropriate control markers, known to enter
cells via specific endocytic pathways, should be selected. As easy as this may sound, for several of the endocytosis
mechanisms described in literature such specific markers may be missing or are constantly debated, since endocytosis
is still a very active field of research. The selection of such control markers is relatively easy in the case of clathrin-
mediated endocytosis, for which molecules such as LDL or transferrin can be used, as here. The selection of
appropriate cargoes to test the efficacy of the inhibitors on pathways other than clathrin-mediated endocytosis
is more complicated. Usually, cholesterol depletion is used to block uptake mediated by caveolae, and molecules
such as cholera toxin B or SV40 as markers for this pathway. However, it has been shown that cholera toxin
seems to be able to enter different cells independently of caveolae and via different mechanisms, including both
clathrin-mediated endocytosis and clathrin-independent endocytosis [55,56]. Even more importantly, the actual role
of caveolae in endocytosis is strongly debated [57,58]. In fact, it has been shown that in many cell types caveolae
do not even pinch off from the plasma membrane [59]. In these cases, just a fraction of caveolae is mobile and
undergoes endocytosis, mainly if activated by a ligand [60]. Molecules such as LacCer can thus be used, as done here,
to confirm the efficacy of cholesterol depletion. Nevertheless, as discussed in the introduction, it is also important
to keep in mind that cholesterol depletion affects several pathways (as also summarized in Table 1); thus, the results
obtained with this compound need to be interpreted with care.
Next to the selected control markers, 50 nm silica NPs were chosen as a common model used in many cell–NP
studies because of their well-known stability even in cell culture medium [52,53]. Furthermore, their size is comparable
with many nanomedicines: drug carriers of 50–100 nm, commonly applied by parenteral administration, are in fact
considered of optimal size to avoid renal clearance and limit macrophage recognition [61,62]. We stress that for studies
on the mechanisms of uptake of NPs and drug carriers, it is crucial to include some information on NP dispersion
and stability in the cell medium used for exposure to cells, as in Supplementary Figure 2 & Table 1 (unfortunately
often missing): dispersion in cell culture medium can lead to agglomeration, and this could strongly affect the
pathways involved in uptake.
Next to NP dispersion and stability, another key factor that needs to be considered for NP uptake studies is
the choice of medium for NP exposure to cells. In fact, it is known that the biomolecular corona that forms on
the surface of nano-sized objects once they are exposed to biological environments strongly affects their biological
behaviour [63,64]. Studying uptake pathways in the complete absence of any form of corona, such as in serum-free
media, may have totally different outcomes than in real applications [53]. Thus, here – as a first step – we have used
a simple condition with NPs dispersed in standard cell culture medium, supplemented with 10% FBS. Further
studies are required to determine uptake mechanisms in the presence of more realistic coronas.
Additionally, particular care was taken in performing uptake experiments as a function of time and to optimize
conditions to allow exposing cells to the NPs in the presence of the inhibitors for relatively long time. Time-
resolved experiments, in fact, provide more complete information on the kinetic of the process and are of particular
importance when studying internalization of larger objects such as nanocarriers, typically occurring slower than
the uptake of proteins or other macromolecules. Furthermore, shorter exposure times can be affected by particle
adhesion to the outer cell membrane, which may confuse the results [49]: thanks to the optimization performed,
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we have been able to expose cells to the inhibitors for up to 6 h, ensuring that the eventual contribution of NPs
adhering outside cells was minimal in comparison with the amount of internalized NPs [48,49].
Overall, optimization of the protocols for the use of the selected panel of pharmacological inhibitors allowed
us to define conditions in which controls showed a good efficacy of the drug tested, without strong effects on cell
viability. Our results clearly show the importance of this aspect, for instance in the case of chlorpromazine and
EIPA (Figures 1 & 2): as these examples illustrate, even though increasing drug concentration may result in lower
uptake (thus, apparently a stronger inhibition), great care has to be taken in interpreting the results. Viability tests
must be included to exclude that the lower uptake is not simply due to toxicity.
The results obtained with dynamin and MBCD in the presence of serum are an interesting example of a unique
nano-specific challenge when using these pharmacological inhibitors for nanomedicine uptake studies: given the
need to include some biological fluids to allow corona formation, some of these compounds – unfortunately –
may become fully ineffective. When available, other compounds not sensitive to the presence of proteins or other
biomolecules should be used, and overall it is essential that similar effects are tested to avoid misinterpretations.
A further aspect to consider is that even when protocols are optimized as we have shown here, reproducibility
with these compounds can remain challenging. Supplementary Figure 7 shows results for independent experiments
to illustrate this and Figure 7 the corresponding averaged results. The observed variability may be connected to small
variations in cell density or drug preparation, which remain difficult to fully control in independent experiments.
For drugs where only minor effects were observed on NP uptake, like chlorpromazine, these were easily lost when
averaging over multiple replicates. Instead, where the inhibition was more substantial, as expected, it was easier to
reproduce it in independent replicates. This overall suggests the need to set relatively high thresholds on inhibition
efficacy.
Based on the results of Figure 7, and using high thresholds on the inhibitory effect (the red line in the figure is
set at 40% inhibition), our results suggested that chlorpromazine effect on silica uptake is questionable, while a
clear effect was observed with cytochalasin D and nocodazole, and upon longer exposure times also with EIPA.
The last challenge is the interpretation of these results to conclude on the pathway involved in the uptake of these
NPs. While our aim in this work is mainly to illustrate the complexity of this question and challenges associated
with the use of pharmacological inhibitors, rather than answering on how these selected model NPs enter cells, we
include some considerations on the possible interpretation of the results.
The results obtained with chlorpromazine seem to exclude clathrin-mediated endocytosis, usually considered
one of the main pathways for the uptake of NPs smaller than 100 nm [11], because of the size of clathrin coated pits.
Other studies, however, have already contradicted similar findings [65,66]. The results obtained with cytochalasin
D and nocodazole point toward an actin-driven mechanism with a clear role also for microtubules, and those
with EIPA suggest that macropinocytosis may be involved at the longer exposure times. Unfortunately, with the
selected panel, we could not conclude on the role of cholesterol and dynamin, which both help to classify uptake
mechanisms.
Conclusion
Answering the question on the mechanisms that nano-sized drug carriers use to enter cells is an essential step for
the drug-delivery community to improve the design of truly successful nanomedicines and targeted drugs. Another
important aspect that this field needs to address is defining what the ‘appropriate corona’ is for a given nanomedicine
application (for instance using bovine serum on human cells is likely not relevant, as is using serum for inhaled
nanomedicines).
At the same time, the field of endocytosis is still highly active in defining and characterizing the different
mechanisms cells use to internalize materials. This poses considerable challenges in highly interdisciplinary fields
such as that of nanomedicine and points toward the need for a closer connection with the endocytosis community.
Within this context, pharmacological inhibitors are often applied to characterize nanomedicine uptake due to
their apparent ease of use. However, stringent controls are required to demonstrate their effect using appropriate
markers (where available). Moreover, toxicity should be monitored, since it could be easily misinterpreted for
efficient inhibition.
Even when conditions are optimized, multiple independent replicate experiments are needed and results can
be highly variable: time-resolved experiments with a high threshold on the inhibitory effect are needed to try to
interpret the outcomes.
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Overall, once applied with all the discussed precautions, pharmacological inhibitors are useful tools to allow
simple screening on the uptake of nano-sized drug carriers. However, determining the pathways involved solely based
on the results obtained with these compounds remains challenging because of the complications discussed here.
Several other methods are available to characterize uptake pathways: these include for instance RNA interference,
knock down or CRISPR/CAS9 to reduce or block the expression of key endocytic proteins, and imaging-based
approaches to determine colocalization with proteins involved in uptake (for instance by immunolabeling and
transmission electron microscopy, or by fluorescence labeling and imaging in live or fixed cells). The combination
of multiple methods among those available (each presenting advantages and limits) is probably the best approach
to try to fully characterize the pathways involved and answer this central question.
Future perspective
Despite its successes, the nanomedicine field has encountered several challenges in developing nano-sized drug
delivery systems with efficient targeting capabilities and limited side effects. The improvement of targeted drugs
requires a better knowledge of the interaction of these nano-sized carriers with live-cells and the body. Such
knowledge will allow one to tune the nanomaterial design to achieve the desired biological behavior. However, both
controlling nanomaterial design to achieve targeting and (as illustrated in this work) characterizing cellular pathways
are extremely challenging tasks: a closer connection between the cell biology and drug-delivery communities is
desirable to be able to tackle such challenges.
Summary points
• Transport inhibitors are very useful tools to characterize nanomedicine uptake pathways; however, they can have
very strong effects on cells, confusing the outcomes.
• To properly use transport inhibitors, careful controls are needed to demonstrate their efficacy and exclude strong
toxicity.
• Reproducibility of results with pharmacological inhibitors can be challenging; therefore, high thresholds on
inhibition efficacy should be set.
• Time-resolved studies of nanoparticle uptake can help to better interpret the results.
• While serum must be used in order to study the uptake of nanomedicines in a realistic biological environment,
some inhibitors such as methyl-β-cyclodextrin and dynasore fully lose their efficacy in the presence of serum.
Different inhibitors which maintain their effect in the presence of serum are required for nanomedicine studies.
• Actin and microtubules seem to be involved in the uptake of 50 nm silica nanoparticles, as also macropinocytosis
at later exposure times.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/full/
10.2217/nnm-2018-0446
Author contributions
V Francia designed the experiments, performed most of the experiments, analyzed and interpreted the data, contributed to the
drafting of the manuscript. C Reker-Smit and G Boel contributed to the optimization of the methods and to the experiments, the
analysis and interpretation of the data and writing of the manuscript. A Salvati designed the experiments, interpreted the data
and wrote the manuscript. All authors approved the final version of the manuscript
Financial & competing interests disclosure
This work was supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and inno-
vation programme under grant agreement no. 637614 (NanoPaths). A Salvati kindly acknowledges the University of Groningen
for additional funding (Rosalind Franklin Fellowship). The authors have no other relevant affiliations or financial involvement with
any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
1546 Nanomedicine (Lond.) (2019) 14(12) future science group
Transport inhibitors to study nano-carrier uptake Research Article
Open access
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/4.0/
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer. 5(3), 161–171 (2005).
2. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653–664 (2010).
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat.
Nanotechnol. 2(12), 751–760 (2007).
• Review on the present knowledge and challenges in nanomedicine for cancer therapy.
4. Yameen B, Choi WI, Vilos C, Swami A, Shi J, Farokhzad OC. Insight into nanoparticle cellular uptake and intracellular targeting. J.
Control. Rel. 190, 485–499 (2014).
5. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat.
Biotechnol. 33(9), 941–951 (2015).
6. Time to deliver. Nat. Biotechnol. 32(10), 961 (2014).
•• This editorial underlines the need for ‘greater understanding of the mechanisms underlying macromolecule transport across cell
membranes’.
7. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 422(6927), 37–44 (2003).
8. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu. Rev. Biochem. 78(1), 857–902 (2009).
• Review about the mechanisms of endocytosis used by cells.
9. Mayor S, Parton RG, Donaldson JG. Clathrin-independent pathways of endocytosis. Cold Spring Harb. Perspect. Biol. 6(6), 1–20 (2014).
10. Ferreira APA, Boucrot E. Mechanisms of carrier formation during clathrin-independent endocytosis. Trends Cell
Biol. 28(3), 188–200 (2018).
11. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and
caveolae-mediated endocytosis. Biochem. J. 377(Pt 1), 159–169 (2004).
12. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian
cells. Nano Lett. 6(4), 662–668 (2006).
13. Verma A, Uzun O, Hu Y et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat.
Mater. 7(7), 588–595 (2008).
14. dos Santos T, Varela J, Lynch I, Salvati A, Dawson KA. Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene
nanoparticles in different cell lines. PLoS ONE 6(9), e24438 (2011).
15. Arvizo RR, Miranda OR, Thompson MA et al. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano
Lett. 10(7), 2543–2548 (2010).
16. Niu Y, Yu M, Meka A et al. Understanding the contribution of surface roughness and hydrophobic modification on silica nanoparticles
for enhanced therapeutic protein delivery. J. Mater. Chem. B 4, 212–219 (2016).
17. Lorenz S, Hauser CP, Autenrieth B, Weiss CK, Landfester K, Maila¨nder V. The softer and more hydrophobic the better: influence of the
side chain of polymethacrylate nanoparticles for cellular uptake. Macromol. Biosci. 10(9), 1034–1042 (2010).
18. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric
nanoparticles. Biomaterials 31(13), 3657–3666 (2010).
19. Lunov O, Syrovets T, Loos C et al. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a
monocytic cell line. ACS Nano 5(3), 1657–1669 (2011).
20. Fro¨hlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomedicine 7, 5577–5591
(2012).
21. Jiang X, Musyanovych A, Ro¨cker C, Landfester K, Maila¨nder V, Nienhaus GU. Specific effects of surface carboxyl groups on anionic
polystyrene particles in their interactions with mesenchymal stem cells. Nanoscale 3(5), 2028–2035 (2011).
22. Yue ZG, Wei W, Lv PP et al. Surface charge affects cellular uptake and intracellular trafficking of chitosan-based
nanoparticles. Biomacromolecules 12(7), 2440–2446 (2011).
23. Digiacomo L, Cardarelli F, Pozzi D et al. An apolipoprotein-enriched biomolecular corona switches the cellular uptake mechanism and
trafficking pathway of lipid nanoparticles. Nanoscale 9(44), 17254–17262 (2017).
24. Mazzolini J, Weber RJ, Chen HS et al. Protein corona modulates uptake and toxicity of nanoceria via clathrin-mediated
endocytosis. Biol. Bull. 231(1), 40–60 (2016).
future science group www.futuremedicine.com 1547
Research Article Francia, Reker-Smit, Boel & Salvati
25. Damke H, Baba T, Van Der Bliek AM, Schmid SL. Clathrin-independent pinocytosis is induced in cells overexpressing a
temperature-sensitive mutant of dynamin. J. Cell Biol. 131(1), 69–80 (1995).
26. Iversen TG, Skotland T, Sandvig K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future
studies. Nano Today 6(2), 176–185 (2011).
•• This is an excellent review discussing the challenges connected to the study of the uptake of nanoparticles, including challenges
connected to the use of transport inhibitors.
27. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J. Control. Rel. 145(3), 182–195 (2010).
28. Vercauteren D, Vandenbroucke RE, Jones AT et al. The use of inhibitors to study endocytic pathways of gene carriers: optimization and
pitfalls. Mol. Ther. 18(3), 561–569 (2010).
•• Research article on the inhibitors of endocytosis and their limits.
29. Al Soraj M, He L, Peynshaert K et al. siRNA and pharmacological inhibition of endocytic pathways to characterize the differential role of
macropinocytosis and the actin cytoskeleton on cellular uptake of dextran and cationic cell penetrating peptides octaarginine (R8) and
HIV-Tat. J. Control. Rel. 161(1), 132–141 (2012).
30. Koivusalo M, Welch C, Hayashi H et al. Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and
Cdc42 signaling. J. Cell Biol. 188(4), 547–563 (2010).
31. Lim JP, Gleeson PA. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol. Cell Biol. 89(8), 836–843 (2011).
32. Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit
formation. J. Cell Biol. 123(5), 1107–1117 (1993).
33. Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and of the transferrin receptor in rat reticulocytes
recycling. J. Cell. Biol. 97(2),329–339 (1983).
34. Vasile E, Simionescu M, Simionescu N. Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the
arterial endothelium in situ. J. Cell Biol. 96(6), 1677–1689 (1983).
35. Marks DL, Singh RD, Choudhury A, Wheatley CL, Pagano RE. Use of fluorescent sphingolipid analogs to study lipid transport along
the endocytic pathway. Methods 36(2), 186–195 (2005).
36. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. Dev.
Cell. 10(6), 839–850 (2006).
37. Kirchhausen T, Macia E, Pelish HE. Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis. Methods
Enzymol. 438(7), 77–93 (2008).
38. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat. Rev. Mol. Cell Biol. 8(8), 603–612 (2007).
39. Hoebeke J, Van Nijen G, De Brabander M. Interaction of oncodazole (R 17934), a new anti-tumoral drug, with rat brain tubulin.
Biochem. Biophys. Res. Commun. 69(2), 319–324 (1976).
40. Subtil A, Dautry-Varsat A. Microtubule depolymerization inhibits clathrin coated-pit internalization in non-adherent cell lines while
interleukin 2 endocytosis is not affected. J. Cell Sci. 110(Pt 19), 2441–2447 (1997).
41. Mundy DI, Machleidt T, Ying YS, Anderson RG, Bloom GS. Dual control of caveolar membrane traffic by microtubules and the actin
cytoskeleton. J. Cell Sci. 115(Pt 22), 4327–4339 (2002).
42. Caviston JP, Holzbaur EL. Microtubule motors at the intersection of trafficking and transport. Trends Cell Biol. 16(10), 530–537 (2006).
43. Schliwa M. Action of cytochalasin D on cytoskeletal networks. J. Cell Biol. 92(1), 79–91 (1982).
44. Lee E, Knecht DA. Visualization of actin dynamics during macropinocytosis and exocytosis. Traffic 3(3), 186–192 (2002).
45. Yarar D, Waterman-Storer CM, Schmid SL. A dynamic actin cytoskeleton functions at multiple stages of clathrin-mediated
endocytosis. Mol. Biol. Cell. 16(2), 964–975 (2005).
46. Cole NB, Lippincott-Schwartz J. Organization of organelles and membrane traffic by microtubules. Curr. Opin. Cell Biol. 7(1), 55–64
(1995).
47. Preta G, Cronin JG, Sheldon IM. Dynasore – not just a dynamin inhibitor. Cell Commun. Signal. 13(1), 24 (2015).
48. Salvati A, Nelissen I, Haase A et al. Quantitative measurement of nanoparticle uptake by flow cytometry illustrated by an interlaboratory
comparison of the uptake of labeled polystyrene nanoparticles. NanoImpact. 9, 42–50 (2018).
49. Lesniak A, Salvati A, Santos-Martinez MJ, Radomski MW, Dawson KA, A˚berg C. Nanoparticle adhesion to the cell membrane and its
effect on nanoparticle uptake efficiency. JACS 135(4), 1438–1444 (2013).
50. Panarella A, Bexiga MG, Galea G et al. A systematic high-content screening microscopy approach reveals key roles for Rab33b, OATL1
and Myo6 in nanoparticle trafficking in HeLa cells. Sci. Rep. 6, 28865 (2016).
51. Gilleron J, Paramasivam P, Zeigerer A et al. Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids
Res. 43(16), 7984–8001 (2015).
52. Shapero K, Fenaroli F, Lynch I, Cottell DC, Salvati A, Dawson KA. Time and space resolved uptake study of silica nanoparticles by
human cells. Mol. Biosyst. 7(2), 371–378 (2011).
1548 Nanomedicine (Lond.) (2019) 14(12) future science group
Transport inhibitors to study nano-carrier uptake Research Article
53. Lesniak A, Fenaroli F, Monopoli MP, A˚berg C, Dawson KA, Salvati A. Effects of the presence or absence of a protein corona on silica
nanoparticle uptake and impact on cells. ACS Nano 6(7), 5845–5857 (2012).
• This article highlights the importance of the presence of serum and the formation of a corona in the study of the uptake of
nanoparticles.
54. Gilleron J, Querbes W, Zeigerer A et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and
endosomal escape. Nat. Biotechnol. 31(7), 638–646 (2013).
55. Torgersen ML, Skretting G, van Deurs B, Sandvig K. Internalization of cholera toxin by different endocytic mechanisms. J. Cell
Sci. 114(Pt 20), 3737–3747 (2001).
56. Lajoie P, Kojic LD, Nim S, Li L, Dennis JW, Nabi IR. Caveolin-1 regulation of dynamin-dependent, raft-mediated endocytosis of
cholera toxin-B sub-unit occurs independently of caveolae. J. Cell. Mol. Med. 13(9B), 3218–3225 (2009).
57. Cheng JPX, Nichols BJ. Caveolae: one function or many? Trends Cell Biol. 26(3), 177–189 (2016).
58. Shvets E, Ludwig A, Nichols BJ. News from the caves: update on the structure and function of caveolae. Curr. Opin. Cell Biol. 29(1),
99–106 (2014).
59. Thomsen P, Roepstorff K, Stahlhut M, van Deurs B. Caveolae are highly immobile plasma membrane microdomains, which are not
involved in constitutive endocytic trafficking. Mol. Biol. Cell 13, 238–250 (2002).
60. Pelkmans L, Zerial M. Kinase-regulated quantal assemblies and kiss-and-run recycling of caveolae. Nature 436(7047), 128–133 (2005).
61. Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat. Mater. 12(11), 958–962 (2013).
62. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615–627
(2010).
63. Monopoli MP, A˚berg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat.
Nanotechnol. 7(12), 779–786 (2012).
•• The authors review how the composition and characteristics of the nanoparticle corona influence the interactions of
nanoparticles with cells.
64. Nel AE, Ma¨dler L, Velegol D et al. Understanding biophysicochemical interactions at the nano–bio interface. Nat. Mater. 8(7), 543–557
(2009).
65. Agarwal R, Singh V, Jurney P, Shi L, Sreenivasan SV, Roy K. Mammalian cells preferentially internalize hydrogel nanodiscs over
nanorods and use shape-specific uptake mechanisms. Proc. Natl Acad. Sci. USA 110(43), 17247–17252 (2013).
66. Lerch S, Dass M, Musyanovych A, Landfester K, Maila¨nder V. Polymeric nanoparticles of different sizes overcome the cell membrane
barrier. Eur. J. Pharm. Biopharm. 84(2), 265–274 (2013).
future science group www.futuremedicine.com 1549

